Pharmaceutical

Holoclara gains Series A financing for worm-derived therapies

Holoclara has secured $16m in a Series A financing to advance new worm-derived therapies targeting allergic and autoimmune diseases.

Jun 30, 2024 - 04:00
Holoclara gains Series A financing for worm-derived therapies
Holoclara has secured $16m in a Series A financing to advance new worm-derived therapies targeting allergic and autoimmune diseases.
Read the original article

Tags:

Previous Article

Alumis raises $250m in IPO as biotech stock stirs

Next Article

Eisai and Biogen launch LEQEMBI for Alzheimer’s in China

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024

STAT+: Pharmalittle: Weight-loss drugs fuel boom for fi...

Oct 10, 2023

STAT+: UnitedHealth executive to head health insurance group AHIP

STAT+: UnitedHealth executive to head health insurance ...

Dec 11, 2023

New study gets beyond BMI in pregnancy to gauge child’s risk of obesity

New study gets beyond BMI in pregnancy to gauge child’s...

Apr 5, 2023